Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists

Latest Vestal Point Capital, LP Stock Portfolio

$1.34Billion– No. of Holdings #60

Vestal Point Capital, LP Performance:
2024 Q2: -9.25%YTD: -9%

Performance for 2024 Q2 is -9.25%, and YTD is -9%.

About Vestal Point Capital, LP and 13F Hedge Fund Stock Holdings

Vestal Point Capital, LP is a hedge fund based in NEW YORK, NY. On 10-Aug-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $1.3 Billions. In it's latest 13F Holdings report, Vestal Point Capital, LP reported an equity portfolio of $1.3 Billions as of 30 Jun, 2024.

The top stock holdings of Vestal Point Capital, LP are JAZZ, CYTK, . The fund has invested 11.9% of it's portfolio in JAZZ PHARMACEUTICALS PLC and 8.4% of portfolio in CYTOKINETICS INC.

The fund managers got completely rid off NEUROCRINE BIOSCIENCES INC (NBIX), ALNYLAM PHARMACEUTICALS INC (ALNY) and ASTRAZENECA PLC stocks. They significantly reduced their stock positions in INARI MEDICAL INC (NARI), GLOBUS MEDICAL INC (GMED) and LIQUIDIA CORP (LQDA). Vestal Point Capital, LP opened new stock positions in JANUX THERAPEUTICS INC (JANX), SAVARA INC (SVRA) and ITEOS THERAPEUTICS INC (ITOS). The fund showed a lot of confidence in some stocks as they added substantially to ULTRAGENYX PHARMACEUTICAL INC (RARE), EXACT SCIENCES CORP (EXAS) and ARCELLX INC (ACLX).
Vestal Point Capital, LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024

Vestal Point Capital, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Vestal Point Capital, LP made a return of -9.25% in the last quarter. In trailing 12 months, it's portfolio return was NA%.

New Buys

Ticker$ Bought
janux therapeutics inc30,370,200
savara inc26,154,700
iteos therapeutics inc25,970,000
axsome therapeutics inc24,150,000
structure therapeutics inc21,991,200
bristol-myers squibb co20,765,000
day one biopharmaceuticals inc17,225,000
immunome inc12,100,000

New stocks bought by Vestal Point Capital, LP

Additions to existing portfolio by Vestal Point Capital, LP

Reductions

Ticker% Reduced
inari medical inc-56.25
globus medical inc-10.00
liquidia corp-8.5
soleno therapeutics inc-4.00
cytokinetics inc-3.49

Vestal Point Capital, LP reduced stake in above stock

Sold off

Ticker$ Sold
geron corp-7,260,000
tg therapeutics inc-15,970,500
lyra therapeutics inc-4,976,000
neurocrine biosciences inc-97,923,200
novavax inc-2,390,000
astrazeneca plc-27,100,000
alnylam pharmaceuticals inc-52,307,500
alpine immune sciences inc-13,874,000

Vestal Point Capital, LP got rid off the above stocks

Sector Distribution

Vestal Point Capital, LP has about 84.2% of it's holdings in Healthcare sector.

Sector%
Healthcare84.2
Others15.8

Market Cap. Distribution

Vestal Point Capital, LP has about 11.9% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP43.5
SMALL-CAP25.6
UNALLOCATED15.8
LARGE-CAP8.2
MEGA-CAP3.7
MICRO-CAP3.1

Stocks belong to which Index?

About 40.1% of the stocks held by Vestal Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others59.8
RUSSELL 200038.6
S&P 5001.5
Top 5 Winners (%)%
ATRA
atara biotherapeutics inc
1115.7 %
INSM
insmed inc
147.0 %
NRIX
nurix therapeutics inc
37.5 %
DYN
dyne therapeutics inc
30.4 %
GMED
globus medical inc
26.9 %
Top 5 Winners ($)$
INSM
insmed inc
29.9 M
GMED
globus medical inc
14.5 M
NRIX
nurix therapeutics inc
2.8 M
DNLI
denali therapeutics inc
2.2 M
AXSM
axsome therapeutics inc
2.0 M
Top 5 Losers (%)%
MGNX
macrogenics inc
-69.1 %
ALXO
alx oncology holdings inc
-48.4 %
SLDB
solid biosciences inc
-45.8 %
VTYX
ventyx biosciences inc
-45.7 %
PASG
passage bio inc
-39.6 %
Top 5 Losers ($)$
CYTK
cytokinetics inc
-33.8 M
ALXO
alx oncology holdings inc
-20.4 M
JAZZ
jazz pharmaceuticals plc
-16.3 M
SLDB
solid biosciences inc
-12.8 M
APLT
applied therapeutics inc
-10.8 M

Vestal Point Capital, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Vestal Point Capital, LP

Vestal Point Capital, LP has 60 stocks in it's portfolio. About 54.9% of the portfolio is in top 10 stocks. CYTK proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Vestal Point Capital, LP last quarter.

Last Reported on: 14 Aug, 2024
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions